Key result
In infants and children with comorbid cardiac diseases, sugammadex administration was associated with a 20% incidence of bradycardia, though no episodes required clinical intervention.
Why the study?
Anecdotal reports noted rare instances of bradycardia and cardiac arrest following sugammadex, prompting evaluation of heart rate changes in pediatric patients with comorbid cardiac diseases.
Does sugammadex cause clinically significant bradycardia in infants and children with comorbid cardiac, cardiovascular, and congenital heart diseases?
Observational (n=99)
No
Does sugammadex cause clinically significant bradycardia in infants and children with comorbid cardiac, cardiovascular, and congenital heart diseases?
In pediatric patients with cardiac comorbidities, sugammadex administration is associated with a 14-20% incidence of bradycardia, but these episodes are self-limited and do not require clinical intervention.
No takes yet. Share an insight, caveat, or question.
Supports monitoring for bradycardia with sugammadex in this population without changing practice; leaves open need for RCTs.
Arends et al. (2020) conducted an observational in Comorbid cardiac, cardiovascular, and congenital heart diseases (n=99). Sugammadex was evaluated on Bradycardia (heart rate below the fifth percentile for age). In infants and children with comorbid cardiac diseases, sugammadex administration was associated with a 20% incidence of bradycardia, though no episodes required clinical intervention.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: